$PXYN Praxsyn Publishes Financial Q3 Results. Gene
Post# of 35426
(Total Views: 62)
Posted On: 11/21/2019 9:53:32 AM
$PXYN Praxsyn Publishes Financial Q3 Results. Generating Revenues.
Press Release | 11/21/2019
WEST PALM BEACH, Florida, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Praxsyn (OTC
XYN, the “Company”) published its 3rd Quarter results yesterday on OTCMarkets.com.
This marks the Company’s return to revenue production with the closing of its first transaction under its new revenue model in the last week of September, generating $41,926 in revenue with $24,457 in gross profit.
Frank Brady, the Company’s CEO stated, “The closing of this transaction and the revenue it brings, proves the viability of the new revenue model. We look forward to selling many, many more portfolios well into the future, and anticipate becoming cash flow highly profitable in the very near future.”
About Praxsyn Corporation
Headquartered in West Palm Beach, Florida, Praxsyn Corporation works to realize the vision of medical professionals to improve the lives of their patients. Additional company information can be found at www.praxsyncorp.com.
With a mid-market private equity firm that invests in growth companies, recapitalizes or backs new executives.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue Praxsyn's business and product development plans and overall market conditions. These forward-looking statements are made as of the date of this press release, and Praxsyn assumes no obligation to update the forward-looking statements.
We may use terms such as “projects,” “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate.
Investor Contact:
Email: investors@praxsyncorp.com
Press Release | 11/21/2019
WEST PALM BEACH, Florida, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Praxsyn (OTC
XYN, the “Company”) published its 3rd Quarter results yesterday on OTCMarkets.com. This marks the Company’s return to revenue production with the closing of its first transaction under its new revenue model in the last week of September, generating $41,926 in revenue with $24,457 in gross profit.
Frank Brady, the Company’s CEO stated, “The closing of this transaction and the revenue it brings, proves the viability of the new revenue model. We look forward to selling many, many more portfolios well into the future, and anticipate becoming cash flow highly profitable in the very near future.”
About Praxsyn Corporation
Headquartered in West Palm Beach, Florida, Praxsyn Corporation works to realize the vision of medical professionals to improve the lives of their patients. Additional company information can be found at www.praxsyncorp.com.
With a mid-market private equity firm that invests in growth companies, recapitalizes or backs new executives.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue Praxsyn's business and product development plans and overall market conditions. These forward-looking statements are made as of the date of this press release, and Praxsyn assumes no obligation to update the forward-looking statements.
We may use terms such as “projects,” “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate.
Investor Contact:
Email: investors@praxsyncorp.com
(0)
(0)